Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel – A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the prognostic score in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.
Conducted post hoc analysis of CABASTY trial and validated with PROSELICA and CARD trials.
Utilized data from international prospective phase 3 trials to compare treatment outcomes.
Analyzed survival rates related to the integrated prognostic score.
Demonstrated a significant correlation between the prognostic score and patient survival.
Identified improved treatment outcomes in patients with higher prognostic scores.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Evaluates prognostic score in metastatic castration-resistant prostate cancer, indicating treatment response.

ClinicalTrials.gov Identifiers: NCT02961257 (CABASTY), NCT01308580 (PROSELICA), NCT02485691 (CARD).

No takes yet. Share an insight, caveat, or question.

Vauchier et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share